F-1/A: HengHong Tech Files for US IPO Amidst China Risks

HengHong Technology Inc. has filed an F-1/A amendment for its initial public offering, aiming to list on the Nasdaq Capital Market, while detailing substantial risks associated with its China-based operations and regulatory landscape.

Summary

• HengHong Technology Inc. is an F-1/A filing for an initial public offering (IPO) of 5,000,000 ordinary shares, with an estimated price range of $6 to $7 per share.
• The company distributes pharmaceutical products in China, primarily Traditional Chinese Medicines (TCMs) and chemical medical products.
• Revenue for the year ended December 31, 2025, was RMB 214,724,541 (US$ 30,705,201), a 7.2% increase from 2024, but net income decreased by 21.5% to RMB 11,960,369 (US$ 1,710,309).
• The company plans to use the net proceeds for strategic acquisitions (45%), expansion of its distribution network and international market development (25%), and working capital.
• Significant risks are highlighted, including those related to China's regulatory environment, potential delisting under the Holding Foreign Companies Accountable Act, and operational challenges.
• The company is a Cayman Islands holding company with its primary operations in China, and its structure involves unique risks for investors.
• Mr. Weixiong Tan, through HengHong Holdings Limited, will control approximately 71.6% of the company's shares post-offering, making it a controlled company under Nasdaq rules.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with the company pursuing an IPO but facing significant risks related to its China-based operations and regulatory environment.

Positives

• Revenue increased by 7.2% to RMB 214,724,541 (US$ 30,705,201) for the year ended December 31, 2025.
• The company has an experienced and stable marketing team with over 80% of staff having more than 10 years of experience.
• A well-developed multi-channel sales system is in place, covering both offline and online distribution.
• The company has a light-asset operational model, focusing capital on product selection, distributor screening, and market promotion.
• The company is seeking to list on the Nasdaq Capital Market, which could provide increased visibility and access to capital.

Negatives

• Net income decreased by 21.5% to RMB 11,960,369 (US$ 1,710,309) for the year ended December 31, 2025.
• Gross profit margin decreased from 22.3% in 2024 to 17.2% in 2025.
• Revenue from promotion and marketing services decreased by 51.6%.
• Selling and marketing expenses decreased by 31.3%, potentially indicating reduced promotional efforts.
• General and administrative expenses increased by 38.5%, largely due to IPO-related professional fees.
• The company is heavily reliant on a single supplier (GDHC), accounting for 93.6% of total purchases in 2025.

Risks

• Significant risks associated with China's regulatory environment, including potential government intervention, changes in policies, and enforcement of laws.
• Potential delisting from Nasdaq due to the Holding Foreign Companies Accountable Act (HFCA Act) if the PCAOB cannot inspect the auditor for three consecutive years.
• Uncertainties regarding PRC cybersecurity laws, data security, and cross-border data transfer regulations.
• The company's corporate structure and operations in China pose risks to investors, including difficulties in enforcing judgments and conducting investigations.
• The company is a controlled company, meaning its majority shareholder can control all matters requiring shareholder approval, potentially leading to conflicts of interest.
• The company has broad discretion in the use of IPO proceeds and may not use them effectively.
• The company is not likely to pay cash dividends in the foreseeable future.
• The company has not obtained necessary permits for all leased properties, potentially exposing it to fines.

Future Outlook

The company plans to use IPO proceeds for strategic acquisitions, expansion of its distribution network, and international market development. The outlook is cautiously optimistic, contingent on navigating significant regulatory and operational risks in China.

Management Comments

• We believe that with our well-developed sales and marketing network and experienced and outstanding team, we are fully capable of occupying a place in the market competition.
• We plan to increase our depth and strength in the promotion and marketing of tonic products, exploit the market potential of tonic products such as Zhuangyao Jianshen Pill, Suoxian Bushen Oral Liquid, Qizi Tianjing Oral Liquid, and build a series of medicinal liquor products.

Industry Context

StockSavvy.ai notes that HengHong operates in China's growing pharmaceutical distribution market, particularly in Traditional Chinese Medicine, which benefits from an aging population and increasing health awareness. However, the industry faces intense competition and evolving regulations.

Corporate Governance

Related Party Transactions

• Purchases of products from GDHC amounted to RMB 168,570,814 in 2025.
• Revenue from promotion and marketing services from SXHC was RMB 5,689,176 in 2025.
• Loans and advances from related party Wei Zhao were RMB 2,657,448 as of December 31, 2025.

Stakeholder Impact

• Shareholders face risks related to China's regulatory environment, potential delisting, and the company's controlled status.
• Investors may experience dilution due to the IPO and potential future equity issuances.
• Employees are subject to PRC labor laws and benefit plan requirements.

Next Steps

• Obtain approval for listing on the Nasdaq Capital Market.
• Complete the initial public offering.
• Utilize IPO proceeds for strategic acquisitions, distribution network expansion, and international market development.
• Continue to navigate PRC regulatory requirements, including CSRC filings.

Key Dates

Recommendation

The company's revenue growth is positive, but the significant decline in net income and gross profit margin, coupled with substantial risks related to its China operations and regulatory environment, warrant a cautious approach. The controlled company status and potential for conflicts of interest also add to the risk profile. While the IPO could provide capital for growth, the uncertainties suggest a 'hold' recommendation pending clearer operational and regulatory stability.

Keywords

HengHong Technology, IPO, Nasdaq listing, pharmaceutical distribution, Traditional Chinese Medicine, China regulatory risk, HFCA Act, VIE structure